Men's Health News

RSS

Overweight men diagnosed with prostate cancer more likely to die from the disease

Men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight, according to a Kaiser Permanente study published today in the journal Obesity Research & Clinical Practice. In patients with more aggressive forms of prostate cancer, the researchers also found an even stronger correlation between obesity and mortality.

30 Oct 2013

NHMRC awards over $6M for Griffith University research projects

Griffith University research projects have been awarded just over $6m in research funding by the prestigious National Health and Medical Research Council.

28 Oct 2013

Study evaluates sexual well-being in SCT survivors using sexual function assessment tools

New research ties preparative procedures and complications associated with blood or bone marrow transplantation (stem cell transplantation, SCT) with diminished sexual health in both men and women who have undergone the lifesaving procedure. Study data, published online today in Blood, the Journal of the American Society of Hematology, confirm chronic graft-versus-host disease, a serious complication that occurs when donor cells attack the recipient's cells, as a potential source of sexual dysfunction and are the first to demonstrate an association between total body irradiation and sexual dysfunction in men.

25 Oct 2013

Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine for its October 24, 2013 issue.

25 Oct 2013

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

Research from Boston University School of Medicine suggests that testosterone treatment in hypogonadal (testosterone deficient) men restores normal lipid profiles and may reduce the risk of cardiovascular disease. These finding currently appear online in the International Journal of Clinical Practice.

24 Oct 2013

Binge drinking increases atherosclerotic progression, stroke mortality risk in men

A Finnish population-based study showed that binge drinking was associated with increased atherosclerotic progression in an 11-year follow-up of middle-aged men. The progression of atherosclerosis was increased among men who consumed 6 drinks or more on one occasion.

21 Oct 2013

Study: Skin tanning gene linked to higher risk for testicular cancer in white men

A gene important in skin tanning has been linked to higher risk for testicular cancer in white men, according to a study led by scientists from the U.S. National Institutes of Health and the University of Oxford in England.

19 Oct 2013

New prognostic tool forecasts survival of patients with advanced prostate cancer

For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.

19 Oct 2013

Simple blood test can help diagnose early-stage lung and prostate cancers

Early-stage lung and prostate cancers as well as their recurrence can be detected with a simple blood test, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

16 Oct 2013

UTMB researchers find high variability in PSA-ordering practice among primary care physicians

Many primary care doctors continue to administer the prostate-specific antigen test to even their oldest patients despite the fact that no medical organization recommends prostate cancer screening for men older than 75, according to new research from the University of Texas Medical Branch at Galveston.

15 Oct 2013

Study evaluates economic cost of cancer across 27 countries of the EU

The first ever study to evaluate the economic cost of cancer across the 27 countries of the EU has found that the total cost of cancer in the EU in 2009 was €126 billion, with cancer in Germany, France, Italy, and the UK together accounting for just over two-thirds of this cost (€83 billion).

15 Oct 2013

Study evaluates possibility of individualisation of castration-resistant prostate cancer management

A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.

12 Oct 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

Researchers explore effects of soy, whey protein supplementation on hormonal responses to resistance exercise

A group of researchers recently expanded upon the limited prior research examining the effects of soy and whey protein supplementation on testosterone, sex hormone binding globulin (SHBG), and cortisol responses to an acute bout of resistance exercise.

11 Oct 2013

$Study examines use of single-fraction radiation treatment for prostate cancer, bone metastases$

Study examines use of single-fraction radiation treatment for prostate cancer, bone metastases

Justin E. Bekelman, M.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues conducted a study to examine whether single-fraction radiation treatment, shown to be as effective as multiple-fraction treatment with less potential for harm, has been incorporated into routine clinical practice for Medicare beneficiaries with prostate cancer and at what cost savings.

9 Oct 2013

Women are more likely to suffer urinary tract infections, but men are more prone to be hospitalized

While women are far more likely to suffer urinary tract infections, men are more prone to be hospitalized for treatment, according to a study by Henry Ford Hospital urologists.

9 Oct 2013

Researchers use ARRAYit Microarray Platform to discover important biomarkers

ARRAYit Corporation reports today that researchers at the National Institutes of Health (NIH), National Cancer Institute (NCI) and Northeastern University have used the ARRAYit Microarray Platform to discover biomarkers important in the treatment of prostate cancer.

8 Oct 2013

Taking multivitamin daily may reduce incidence of cancer in men

Major diseases that stem from vitamin deficiencies are rare in the U.S., where food is abundant and rich in vital nutrients, explains David J. Park, DO, an AOA board-certified family physician in Henderson, Nev., during the American Osteopathic Association's (AOA) OMED 2013, the Osteopathic Medical Conference & Exposition taking place this week in Las Vegas.

5 Oct 2013

Men who believe in God less likely to take drugs than atheists

Young Swiss men who say that they believe in God are less likely to smoke cigarettes or pot or take ecstasy pills than Swiss men of the same age group who describe themselves as atheists. Belief is a protective factor against addictive behaviour. This is the conclusion reached by a study funded by the Swiss National Science Foundation.

4 Oct 2013

Researchers show that men experience more harm than good from routine PSA screening

Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm than good from routine PSA screening, according to research to be presented on Monday by Professor Mathieu Boniol, at the 2013 European Cancer Congress (ECC2013).

1 Oct 2013